Update information

Update information

December 2021: We have reviewed the evidence and made a new recommendation on risk stratification for people with newly diagnosed prostate cancer. This recommendation is marked [2021].

We have also made changes to other recommendations without an evidence review to reflect the change in risk stratification model. These recommendations are marked [2008, amended 2021], [2014, amended 2021] or [2019, amended 2021].

Recommendations marked [2008], [2014] or [2019] last had an evidence review in 2008, 2014 or 2019 respectively. Changes made to recommendations in 2014 that did not come from a new evidence review are marked [2008, amended 2014].

We added links to our interventional procedures guidance on focal therapy using high-intensity focused ultrasound for localised prostate cancer and focal therapy using cryoablation for localised prostate cancer (see recommendation 1.3.28).

May 2019: We reviewed the evidence and made new recommendations on diagnosis, treatment and monitoring for people with prostate cancer.

Minor changes since publication

May 2022: We amended the explanation of how recommendations 1.2.14 and 1.2.15 might affect practice, to clarify how the CPG 4 and 5 groups align with the previous high-risk group.

December 2021: Minor changes to redirect NICE Pathways links.

November 2020: We corrected the unit of measurement for PSA velocity to nanogram/ml/year in recommendations 1.2.11 and 1.2.12.

ISBN: 978-1-4731-3375-4

  • National Institute for Health and Care Excellence (NICE)